The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may be the first pill specifically approved for female pattern hair loss.
An article from
Dive Brief
The Phase 2 data exceeded expectations, lifting company shares as high as nearly $130 apiece and building the case for what may be the first pill specifically approved for female pattern hair loss.
Published July 16, 2026
An oral form of minoxidil developed by Veradermics succeeded in a Phase 2 trial in female pattern hair loss.
Veradermics declares first efficacy win in women for hair loss drug
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with Mild-to-Moderate Pattern Hair Loss
Why Hollywood’s Follicle-Challenged Stars Are Harvesting Their Hair
New Peer-Reviewed Study Published in Dermatology and Therapy Adds to Clinical Evidence Showing Nutrafol Hair Growth Nutraceuticals Improve Hair Growth in Women
Veradermics' oral VDPHL01 shows first efficacy data in women, boosting hair count 22.7 hairs/cm² at 6 months; Phase 2/3 trial due…
Veradermics to Hold Conference Call to Discuss Study ‘207’ Phase 2 Clinical Trial Results of VDPHL01 in Females with…
That miracle pill you’ve read about? Two years out. Banking what you have for future cloning could be the solution you seek.
Nearly two years after clinical setbacks cratered Q32’s stock price, new results showed hair growth improvements that surpassed…
Veradermics to Present at Upcoming June Investor Conferences
Hair Restoration Institute of Minnesota Reports Strong Early Patient Response to Dutasteride Mesotherapy
